RT Journal Article
SR Electronic
T1 Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 871
OP 877
DO 10.2967/jnumed.117.203570
VO 59
IS 6
A1 Roberto A. Salas Fragomeni
A1 Tali Amir
A1 Sara Sheikhbahaei
A1 Susan C. Harvey
A1 Mehrbod S. Javadi
A1 Lilja B. Solnes
A1 Ana P. Kiess
A1 Mohamad E. Allaf
A1 Martin G. Pomper
A1 Michael A. Gorin
A1 Steven P. Rowe
YR 2018
UL http://jnm.snmjournals.org/content/59/6/871.abstract
AB Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is highly overexpressed on prostate cancer epithelial cells and for which there is a growing body of literature examining the role of small-molecule and antibody radiotracers targeted against this protein for prostate cancer detection and therapy. Despite its name, PSMA is also expressed, to varying degrees, in the neovasculature of a wide variety of nonprostate cancers; indeed, the pathology literature is replete with promising immunohistochemistry findings. Several groups have begun to correlate those pathology-level results with in vivo imaging and therapy in nonprostate cancers using the same PSMA-targeted agents that have been so successful in prostate cancer. The potential to leverage radiotracers targeted to PSMA beyond prostate cancer is a promising approach for many cancers, and PSMA-targeted agents may be able to supplement or fill gaps left by other agents. However, to date, most of the reported findings with PSMA-targeted radiotracers in nonprostate malignancies have been in case reports and small case series, and the field must adopt a more thorough approach to the design and execution of larger prospective trials to realize the potential of these promising agents outside prostate cancer.